Oncomedics has developped and published the Oncogramme on ovarian cancer.
Oncomedics has developped and published the Oncogramme on ovarian cancer: The Oncogramme allowed a 92% culture success rate, with proliferation of cultured ovarian tumour cells. Ex vivo
ovarian tumour models obtained also maintained heterogeneity of cells found in patient’s cancer tissue, while fibroblast colonization and survival of immune cells were both prevented. Moreover, cell death analysis provided for each tumour
individual drug profiles termed Oncogramme, with statistically significant values. Oncogramme on human ovary tumour samples is an ex vivo method that can predict patient cell sensitivities to drugs. This test now needs to be validated through
a phase I clinical trial.